Immunomodulation is an established treatment strategy in multiple myeloma with thalidomide and its derivatives lenalidomide and pomalidomide as its FDA approved representatives. Just recently the method of action of these cereblon binding molecules was deciphered and results from large phase 3 trials confirmed the backbone function of this drug family in various combination therapies. This review details the to-date knowledge concerning mechanism of IMiD action, clinical applications and plausible escape mechanisms in which cells may become resistant/refractory to cereblon binding molecule based treatment.
Keywords: Aiolos; Cereblon; Cereblon binding molecules; IMiDs; Ikaros; Lenalidomide; Multiple myeloma; Pomalidomide; Thalidomide.
Published by Elsevier Ltd.